These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 15465097

  • 1. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease.
    Tanaka M, Namiki C, Thuy DH, Yoshida H, Kawasaki K, Hashikawa K, Fukuyama H, Kita T.
    J Neurol Sci; 2004 Oct 15; 225(1-2):135-41. PubMed ID: 15465097
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
    Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, Donepezil MSAD Study Investigators Group.
    Int J Geriatr Psychiatry; 2005 Jun 15; 20(6):559-69. PubMed ID: 15920715
    [Abstract] [Full Text] [Related]

  • 3. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
    Borkowska A, Ziolkowska-Kochan M, Rybakowski JK.
    Hum Psychopharmacol; 2005 Aug 15; 20(6):409-14. PubMed ID: 15991260
    [Abstract] [Full Text] [Related]

  • 4. Use of serum insulin-like growth factor-I levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease.
    Tei E, Yamamoto H, Watanabe T, Miyazaki A, Nakadate T, Kato N, Mimura M.
    Growth Horm IGF Res; 2008 Feb 15; 18(1):47-54. PubMed ID: 17714966
    [Abstract] [Full Text] [Related]

  • 5. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
    Frölich L, Ashwood T, Nilsson J, Eckerwall G, Sirocco Investigators.
    J Alzheimers Dis; 2011 Feb 15; 24(2):363-74. PubMed ID: 21258153
    [Abstract] [Full Text] [Related]

  • 6. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
    Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, Zhang R, Bahra R.
    Int J Geriatr Psychiatry; 2004 Jan 15; 19(1):58-67. PubMed ID: 14716700
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V, Haglund A, Kowalski J, Langworth S, Winblad B.
    Dement Geriatr Cogn Disord; 2008 Jan 15; 26(5):458-66. PubMed ID: 18984956
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
    Oka M, Nakaaki S, Negi A, Miyata J, Nakagawa A, Hirono N, Mimura M.
    Psychogeriatrics; 2016 Mar 15; 16(2):121-34. PubMed ID: 26114924
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
    Sakka P, Tsolaki M, Hort J, Hager K, Soininen H, López Pousa S, Li C, Schwam E.
    Curr Med Res Opin; 2007 Dec 15; 23(12):3153-65. PubMed ID: 17988434
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A, Gauthier S, Perdomo C.
    Int J Geriatr Psychiatry; 2007 Aug 15; 22(8):806-12. PubMed ID: 17199235
    [Abstract] [Full Text] [Related]

  • 14. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R.
    Curr Med Res Opin; 2006 Mar 15; 22(3):483-94. PubMed ID: 16574032
    [Abstract] [Full Text] [Related]

  • 15. Effects of donepezil on Alzheimer's disease: the relationship between cognitive function and rapid eye movement sleep.
    Mizuno S, Kameda A, Inagaki T, Horiguchi J.
    Psychiatry Clin Neurosci; 2004 Dec 15; 58(6):660-5. PubMed ID: 15601392
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD).
    Giordano M, Dominguez LJ, Vitrano T, Curatolo M, Ferlisi A, Di Prima A, Belvedere M, Barbagallo M.
    Arch Gerontol Geriatr; 2010 Dec 15; 51(3):245-9. PubMed ID: 19969381
    [Abstract] [Full Text] [Related]

  • 18. Two galantamine titration regimens in patients switched from donepezil.
    Engedal K, Davis B, Richarz U, Han J, Schäuble B, Andreasen N.
    Acta Neurol Scand; 2012 Jul 15; 126(1):37-44. PubMed ID: 21992111
    [Abstract] [Full Text] [Related]

  • 19. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease.
    Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O, Zhang R, Xu Y, Sun Y, Knox S, Richardson S, Mackell J.
    Int J Geriatr Psychiatry; 2011 Feb 15; 26(2):150-7. PubMed ID: 20597141
    [Abstract] [Full Text] [Related]

  • 20. 1-H MRS changes in dorsolateral prefrontal cortex after donepezil treatment in patients with mild to moderate Alzheimer's disease.
    Henigsberg N, Kalember P, Hrabać P, Rados M, Bajs M, Rados M, Kovavić Z, Loncar M, Madzar T.
    Coll Antropol; 2011 Jan 15; 35 Suppl 1():159-62. PubMed ID: 21648328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.